Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire November 06, 2025 Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key appointments in business development and human resources Cash […]